Holen Sie sich die Stockscreener-App
4.65
4.49%
0.20
Handel nachbörslich:
4.72
0.07
+1.51%
Karyopharm Therapeutics Inc Aktie (KPTI) Neueste Nachrichten
US$25.92: That's What Analysts Think Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Is Worth After Its Latest Results - simplywall.st
Karyopharm Therapeutics’ SWOT analysis: biotech firm’s stock faces pivotal year - Investing.com
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Lags Revenue Estimates - MSN
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q2 2025 Earnings Call Transcript - Insider Monkey
Karyopharm’s Earnings Call: Clinical Wins Amid Financial Strain - TipRanks
Karyopharm Therapeutics shares rise 1.03% premarket after reporting Q2 earnings. - AInvest
Karyopharm Therapeutics Reports Q2 Loss Amid Revenue ShortfallNews and Statistics - IndexBox
Karyopharm Therapeutics: Q2 Earnings Snapshot - Connecticut Post
Karyopharm Therapeutics Inc (KPTI) Q2 2025 Earnings Call Highlights: Navigating Financial ... - Yahoo Finance
Karyopharm Therapeutics Inc (KPTI) Q2 2025 Earnings Call Highlights: Navigating Financial ... By GuruFocus - Investing.com Canada
Karyopharm Therapeutics Reports Q2 2025 Earnings - TipRanks
Karyopharm’s Revenue Dips As Drug Sales Inch Upward - Finimize
Karyopharm Sees Mixed Q2 As XPOVIO Sales Climb - Finimize
Karyopharm outlines $1B peak U.S. revenue opportunity in myelofibrosis with pivotal Phase III data expected by March 2026 - MSN
Karyopharm Therapeutics Sees $1B Peak Revenue Potential in Myelofibrosis by 2026 - AInvest
Karyopharm Reports Q2 2025 Financial Results, Updates Guidance, and Explores Financing and Strategic Alternatives - AInvest
Karyopharm Therapeutics Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:KPTI) - Seeking Alpha
Earnings call transcript: Karyopharm Q2 2025 sees revenue decline amid strategic shifts - Investing.com
Karyopharm Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Transcript : Karyopharm Therapeutics Inc., Q2 2025 Earnings Call, Aug 11, 2025 - MarketScreener
Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress - Citizen Tribune
Karyopharm Q2 2025 slides: Myelofibrosis pivot amid mixed financial results By Investing.com - Investing.com Nigeria
Karyopharm Therapeutics Q2 revenue falls 11% - MarketScreener
Karyopharm Therapeutics Inc. SEC 10-Q Report - TradingView
Karyopharm Q2 rev. $37.9mln, up 6% YoY; updates FY guidance. - AInvest
Multi Factor Analysis Ranks Karyopharm Therapeutics Inc. as Strong BuyMomentum Based Equity Trading Plans Reviewed - beatles.ru
Layoff Tracker: Bicycle, Tune, Iovance, Precision Downsize to Conserve Cash - BioSpace
Earnings Outlook For Karyopharm Therapeutics - 富途牛牛
Visual trend scoring systems applied to Karyopharm Therapeutics Inc.Technical Reversal Setup with Risk Limits - Newser
Automated trading signals detected on Karyopharm Therapeutics Inc.Free Community Strategy With High Win Rate - Newser
Chart based exit strategy for Karyopharm Therapeutics Inc.Secure Entry Point Finder with Analysis - Newser
How moving averages guide Karyopharm Therapeutics Inc. tradingMarket Timing Strategy with Technical Filters - Newser
Karyopharm Therapeutics shares rise 1.78% after-hours following Bicycle Therapeutics' board expansion. - AInvest
Karyopharm Therapeutics Inc expected to post a loss of $4.10 a shareEarnings Preview - TradingView
Tick level data insight on Karyopharm Therapeutics Inc. volatilityTechnical Trade Plan with Entry Checklist - Newser
How Karyopharm Therapeutics Inc. stock reacts to Fed policy changesFree Weekly Potential Breakout Stock List - Newser
Karyopharm Therapeutics Inc (KPTI) Q2 2025 Earnings Report Preview: What To Expect - Yahoo Finance
What data driven models say about Karyopharm Therapeutics Inc.’s futureBuy Strategy Review With Performance Summary - Newser
Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025 - Eastern Progress
Karyopharm Therapeutics Inc. stock prediction for this weekAI Swing Strategy Signal Forecasting System - Newser
Candlestick signals on Karyopharm Therapeutics Inc. stock todayHigh Reward Picks with Tight Risk Control - Newser
Is a relief rally coming for Karyopharm Therapeutics Inc. holdersFast Entry Strategy with Price Prediction - Newser
Karyopharm to Report Second Quarter 2025 Financial Results on Au - GuruFocus
Will Karyopharm Therapeutics Inc. stock split in the near futureStock Price Prediction Using AI Tools - Newser
Karyopharm Therapeutics Inc. Sees Spike in Bullish Option FlowPattern Alert With ROI Driven Strategy Shared - beatles.ru
Is Karyopharm Therapeutics Inc. a growth stock or a value stockTriple-digit profit margins - Jammu Links News
Why is Karyopharm Therapeutics Inc. stock attracting strong analyst attentionUnlock real-time trading signals for gains - Jammu Links News
What makes Karyopharm Therapeutics Inc. stock price move sharplyUnlock powerful portfolio management tools - Jammu Links News
How does Karyopharm Therapeutics Inc. compare to its industry peersAchieve impressive returns with smart timing - Jammu Links News
What is the risk reward ratio of investing in Karyopharm Therapeutics Inc. stockBuild a winning portfolio with smart picks - Jammu Links News
Will Karyopharm Therapeutics Inc. see short term momentumFree AI Screening for Swing Trade Picks - Newser
What institutional investors are buying Karyopharm Therapeutics Inc. stockFree Daily Trading Room Entry - Jammu Links News
Should I hold or sell Karyopharm Therapeutics Inc. stock in 2025Overwhelming financial success - Jammu Links News
When is Karyopharm Therapeutics Inc. stock expected to show significant growthCapitalize on fast-moving stock opportunities - Jammu Links News
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Eastern Progress
Is Karyopharm Therapeutics Inc. stock overvalued or undervaluedRapid portfolio appreciation - Jammu Links News
Why Karyopharm Therapeutics Inc. stock attracts strong analyst attentionEntry Signal Momentum Tracker Review - beatles.ru
0.11%
1.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):